More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by...
More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by Watson's generic versions of the Lipitor cholesterol drug and Lovenox blood thinner, and a rise in international sales. 2012 guidance: adjusted EPS $5.55-$5.80 and revenue $5.5B vs. consensus of $5.80 and $5.5B.
Check out Seeking Alpha’s new Earnings Center »
From other sites
Video at CNBC.com (May 22, 2015)
Video at CNBC.com (May 11, 2015)
Video at CNBC.com (Apr 9, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 30, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs